...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Growth hormone and IGF research: Official journal of the Growth Hormone Research Society and the International IGF Research Society >Could calgranulins and advanced glycated end products potentiate acromegaly pathophysiology?
【24h】

Could calgranulins and advanced glycated end products potentiate acromegaly pathophysiology?

机译：Calgranulins和先进的糖化末端产品有权烦恼性症状病理生理学吗？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Growth hormone (GH) exerts a diverse set of effects across many tissues including fat, muscle, bone, kidney, heart, and liver. GH is also a diabetogenic hormone in that it inhibits the actions of insulin. Acromegaly, a condition traditionally characterized by increased levels of growth hormone secretion as a result of pituitary adenoma, results in increased tissue growth, lipolysis, and can result in patients with hyperglycemia and hy-perinsulinemia. While current treatment modalities have greatly improved prognoses for most patients, a significant number present clinical symptoms of acromegaly with elevated levels of IGF-1 in the absence of increased GH levels, a phenomenon known as micromegaly. This condition presents a challenge to most currently used treatments since the high circulating IGF-1 levels are independent of elevated levels of GH. It has been previously shown that advanced glycation end products (AGE) can stimulate IGF-1 secretion by human mono-cytes in vitro, demonstrating a possible mechanism for increased IGF-1 levels. To further investigate AGE/GH/ IGF-1 interaction, we have reanalyzed a publicly available RNAseq dataset from subcutaneous adipose tissue of patients with acromegaly. S100A1, a member of the calgranulin family of proteins and ligand of the AGE receptor, was shown to be significantly upregulated in patients with acromegaly. These findings identify an important consideration that may help explain the counterintuitive nature of micromegaly, while simultaneously providing new insight into the role of GH in diabetic, inflammatory, and immune pathologies.
机译：生长激素（GH）在许多组织中施加多样化的效果，包括脂肪，肌肉，骨骼，肾脏，心脏和肝脏。 GH也是一种糖糖激素，其抑制了胰岛素的作用。 Acromegaly，一种传统形式的病症，其特征在于垂体腺瘤的增长激素分泌水平增加，导致组织生长增加，脂解，并且可以导致高血糖和Hy-Persinnemia的患者。虽然目前的治疗方式对于大多数患者来说具有大大改善的预期，但在没有增加的GH水平的情况下，IGF-1水平升高的临床症状的显着数量较高，这是一种称为MicromeGaly的现象。由于高循环IGF-1水平与GH的升高，这种情况提出了对当前使用的治疗的挑战。先前已经表明，先进的糖化末端产品（年龄）可以在体外刺激人单胞嘧啶的IGF-1分泌，证明了增加IGF-1水平的可能机制。为了进一步调查年龄/ GH / IGF-1相互作用，我们已经从患者的皮下脂肪组织中重新分析了可公开的RNASEQ数据集，患者的患者的患者的患者。 S100A1是Calgranulin蛋白质蛋白质和年龄受体的配体的成员，在患者患者中显着上调。这些调查结果确定了一个重要的考虑因素，可能有助于解释MicromeGaly的反向性质，同时同时为GH在糖尿病，炎症和免疫病变中的作用提供新的洞察力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号